

Special Issue

Radiation Therapy for Breast Cancers

Message from the Guest Editor

In recent years, advances in treatment techniques and imaging systems have constantly improved the precision of radiotherapy, which further improved the already existing potential for breast cancer treatment. This Special Issue will focus on how technical achievements such as respiratory gating, intraoperative radiotherapy, image-guided radiotherapy (IGRT), high-precision stereotactic treatments and radiosurgery, and partial breast irradiation can be optimally used to increase the effectiveness and reduce the toxicity of adjuvant radiation therapy in early breast cancer. In addition, we aim to investigate the potential of re-irradiation, stereotactic ablative therapy, and palliative radiotherapy for recurrent and metastatic breast cancer. Insights into complementary and alternative medicine complement this Special Issue, enabling a comprehensive overview and outlook on optimized radiotherapy approaches in breast cancer.

Guest Editor

Prof. Dr. Stephanie Elisabeth Combs

Department of Radiation Oncology, Technical University of Munich (TUM), Munich, Germany/Neuherberg, Germany

Deadline for manuscript submissions

closed (31 October 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/66195

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)